Sugi Predict

Sugi Predict / Compounds / SCHEMBL9900562

SCHEMBL9900562

SCHEMBL9900562

Cc1ccc(O)c2c1OCC2(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 3/20 0.34
▸ ESR2 Q92731 3/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ TP53 P04637 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ KDM4E B2RXH2 4/20 0.31
▸ HPGD P15428 4/20 0.31
▸ MAPT P10636 3/20 0.31
▸ RECQL P46063 3/20 0.31
▸ TDP1 Q9NUW8 3/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ G6PD P11413 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ MAPK1 P28482 2/20 0.31
▸ NSD2 O96028 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CASP7 P55210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438009 1.00 ESR1 (0.34) ESR1ESR2MAOAMAOBTP53
SCHEMBL21581562 0.84 KDM4E (0.33) KDM4EHPGDALDH1A1ALOX5PTGS1
SCHEMBL16659186 0.82 TP53 (0.38) ESR1ESR2MAOAMAOBTP53
SCHEMBL15011718 0.80 HTR1A (0.36) ESR1ESR2TP53CYP1A2KDM4E
SCHEMBL9904807 0.80 MAOA (0.33) ESR1ESR2MAOAMAOBTP53
SCHEMBL18199054 0.78 HPGD (0.33) ESR1ESR2HPGD
SCHEMBL9923814 0.77 ESR1 (0.34) ESR1ESR2MAOAMAOB
SCHEMBL20777043 0.75 KDM4E (0.31) TP53KDM4EHPGDMAPTRECQL
SCHEMBL24350107 0.75 PTGS2 (0.43) ALOX5PTGS1PTGS2
SCHEMBL25025728 0.75 LMNA (0.36) KDM4EMAPTALDH1A1CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US claimed
US-9422272-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2016-08-23 — — US claimed
EP-2788339-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 — — EP claimed
US-20150336936-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2015-11-26 — — US claimed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP claimed
US-20140323508-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2014-10-30 — — US claimed
EP-2788339-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2014-10-15 — — EP claimed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP claimed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US claimed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 — — WO claimed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO claimed
US-20240327406-A1 POTASSIUM CHANNEL MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2024-10-03 — — US disclosed
EP-3867247-B1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LTD (GB) 2024-07-24 — — EP disclosed
EP-4384504-A1 POTASSIUM CHANNEL MODULATORS Autifony Therapeutics Limited (GB) 2024-06-19 — — EP disclosed
CN-117751119-A Potassium channel modulators 奥蒂福尼疗法有限公司 2024-03-22 — — CN disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327406-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNN2, KCNN1 ESR1 3921/4885ESR2 1524/4885MAOA 2641/4885
US-20150336936-A1 NOVEL COMPOUNDS KCNN3, KCNN2, KCNN1 ESR1 4407/4885ESR2 2125/4885MAOA 2419/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ESR1 4858/4885ESR2 4341/4885MAOA 2050/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ESR1 4858/4885ESR2 4341/4885MAOA 2050/4885
US-20140323508-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 ESR1 3101/4885ESR2 1076/4885MAOA 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.